Clinical Trials in Philadelphia

Showing 10441-10460 of 20,904 trials

Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma

NCT01057121

This phase I/II trial studies the side effects and best dose of lenalidomide and to see how well it works in treating patients with acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS). Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor.

National Cancer Institute (NCI)38 participantsStarted Aug 2010

Los Angeles, California, United States • San Diego, California, United States • San Francisco, California, United States +10 more locations

COMPLETEDNA< 1 mile

Way to Cure HCV Adherence

NCT02472925

This is a 3-arm, multi-center, patient-randomized, field evaluation of the "Way to Cure" behavioral interventions on medication adherence in HCV.

Hepatitis C

University of Pennsylvania60 participantsStarted Jun 2015

Philadelphia, Pennsylvania, United States • Philadelphia, Pennsylvania, United States

Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma

Way to Cure HCV Adherence

Find Trials by Condition in Philadelphia

Bridging ED to Outpatient AUD Therapy With Naltrexone

Safety Study of MGA271 in Refractory Cancer

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors

Using Connected Health to Increase Lung Cancer Screening

Opioid Taper Study

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

Feasibility of Telemedicine Medical Abortion

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma

Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors

MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer

An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Study to Determine Safety and Dose of NJH395 in Non-breast HER2+ Advanced Cancer